Skip to main content
S&P 5007,619.98-0.48%DOW52,421.20-0.29%NASDAQ26,186.41-0.56%BTC$79,156.00+2.45%ETH$2,563.87+2.28%GOLD$4,326.60-1.87%OIL$101.88+1.83%
Smart Investors Daily
PP

NASDAQ · PPCB

Propanc Biopharma, Inc. Common Stock

Healthcare · Biotechnology

$0.92

Down-$0.07 (-7.71%)

Updated Sep 14, 2026, 8:15 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
9.77M
P/E ratio
-0.15
Dividend yield
0.00%
52-week range
$0.09 – $6.79
Volume
233.02K
Avg. volume
330.85K

Price performance

PPCB price history

1M range · 19 trading sessions · Daily adjusted prices

PPCB closed at $0.92 after 19 trading sessions, down 19.91% for the selected period.

Last close
$0.92
Period change
-19.91%
Period low
$0.92
Period high
$2.23
Daily close
View OHLC price history
PPCB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$0.9222$0.9349$0.8744$0.921233.02K
Sep 10, 2026$0.9734$0.9762$0.936$0.9428129K
Sep 9, 2026$1.01$1.03$0.915$0.99304.91K
Sep 8, 2026$1.02$1.0399$0.9914$1.03176.67K
Sep 4, 2026$1.05$1.05$0.9715$1.01194.4K
Sep 3, 2026$1.03$1.0351$0.9697$1.02353.67K
Sep 2, 2026$1.10$1.16$1.00$1.03529.87K
Sep 1, 2026$1.27$1.275$1.11$1.13623.22K
Aug 31, 2026$1.29$1.48$1.25$1.35805.07K
Aug 28, 2026$1.93$1.94$1.31$1.354.06M
Aug 27, 2026$3.51$4.13$1.98$2.2397.32M
Aug 26, 2026$1.119$1.12$1.07$1.079.77K
Aug 25, 2026$1.14$1.16$1.0801$1.1315.25K
Aug 24, 2026$1.10$1.19$1.08$1.15523.02K
Aug 21, 2026$1.12$1.12$1.05$1.0825.22K
Aug 20, 2026$1.13$1.18$1.10$1.1020.83K
Aug 19, 2026$1.185$1.185$1.10$1.1436.89K
Aug 18, 2026$1.12$1.1938$1.10$1.1633.09K
Aug 17, 2026$1.25$1.27$1.15$1.1546.6K

Latest PPCB news

The latest Smart Investors Daily articles mentioning PPCB.

Stock researchCompany · Overview

PPCB research

Overview

Company profile and research snapshot.

Company profile

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across AustraliaMELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced plans to commence a world-first Phase 1b first-in-human (FIH) study of PRP in February 2027.

Benzinga · Aug 27, 2026

Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings

U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings. European and Asian markets closed mostly lower.

Yahoo · Aug 12, 2026

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Contrasting Science with Revolution Medicines and ErascaMELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines, Inc. and Erasca, Inc. The Company articulates why PRP’s unique m

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By